Bildkälla: Stockfoto

Acarix Q4’21: Focus on the US - Redeye

Redeye leaves its view on Acarix following the announcement of its year-end report, which overall came in short of our estimates.

Redeye leaves its view on Acarix following the announcement of its year-end report, which overall came in short of our estimates.
Börsvärldens nyhetsbrev
ANNONSER